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Abstract
Rationale—Prescription opioid misuse and high dose opioid use may result in allostatic 
dysregulation of hedonic brain circuitry, leading to reduced emotion regulation capacity. In 
particular, opioid misuse may blunt the ability to experience and upregulate positive affect from 
natural rewards.
Objectives—The purpose of this study was to examine associations between opioid use/misuse 
and autonomic indices of emotion regulation capability in a sample of chronic pain patients 
receiving prescription opioid pharmacotherapy.
Methods—Chronic pain patients taking long-term opioid analgesics (N = 40) completed an 
emotion regulation task while heart rate variability (HRV) was recorded, as well as self-report 
measures of opioid misuse, craving, pain severity, and emotional distress. Based on a validated 
cut-point on the Current Opioid Misuse Measure, participants were grouped as opioid misusers or 
non-misusers. Opioid misuse status and morphine equivalent daily dose (MEDD) were examined 
as predictors of HRV and self-reports of emotion regulation.
Results—Opioid misusers exhibited significantly less HRV during positive and negative emotion 
regulation, and significantly less positive affect, than non-misusers, after controlling for 
confounders including pain severity and emotional distress. MEDD was inversely associated with 
positive emotion regulation efficacy.
Conclusion—Findings implicate the presence of reward processing deficits among chronic pain 
patients with opioid-misusing behaviors, and opioid dosage was associated with deficient emotion 
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regulation, suggesting the presence of compromised top-down cognitive control over bottom-up 
hedonic processes. Emotion regulation among opioid misusers may represent an important 
treatment target.
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1. Introduction
Prolonged use of prescription opioid analgesics may result in opioid misuse and addiction 
due to pharmacologic actions of opioids on mesocorticolimbic brain reward circuits (Volkow 
et al. 2016). Approximately 21% to 29% of chronic pain patients receiving long-term opioid 
analgesic pharmacotherapy exhibit opioid misuse behaviors including unauthorized dose 
escalation or attempts to self-medicate negative affect with opioids (Vowles et al. 2015). A 
recent investigation of treatment-seeking opioid dependent individuals found that 95% 
reported using opioids to alleviate negative affective states (Garland et al. 2015b). Thus, 
misuse of opioids to regulate emotional well-being may be prevalent in some populations.
According to the allostatic model (Koob and Le Moal 2001), the attempt to maintain 
hedonic homeostasis via opioid misuse may be undermined by increasing pharmacologic 
tolerance coupled with recurrent pain and affective distress, resulting in craving (Martel et 
al. 2014) and opioid dose escalation (Shurman et al. 2010). Ironically, increased opioid self-
administration may shift the hedonic set point, resulting in insensitivity to natural rewards, a 
blunting of positive emotion, and worsening dysphoria (Koob and Le Moal 2008). When 
coupled with the disruptions in self-regulation that lead to and result from addictive behavior 
(Tang et al. 2015), these changes may drive a downward spiral of dependence on opioids 
(Garland et al. 2013).
Consistent with this theory implicating impaired cognitive control over reward system 
function, opioid misuse and opioid dose escalation among chronic pain patients should 
impair emotion regulation – and in particular, blunt the ability to experience and upregulate 
positive affect in response to naturally rewarding stimuli. Though reward processing deficits 
have been observed in illicit opiate dependence (Lubman et al. 2009; Huhn et al.), only one 
study has demonstrated this phenomenon among opioid-misusing pain patients by 
identifying significantly attenuated cardiac-autonomic regulation (i.e., heart rate variability - 
HRV) during attention to natural reward-related images in a dot probe task (Garland et al. 
2015a).
Attending to emotionally-salient stimuli and regulating one’s emotional response to such 
stimuli is thought to elicit downstream activation of a central-autonomic network (e.g., 
medial prefrontal cortex → anterior cingulate cortex and anterior insula → central nucleus 
of the amygdala → hypothalamus → nucleus of the solitary tract → ventrolateral 
medullary) with downstream effects on visceral and peripheral physiology, including the 
beat-to-beat modulation of heart rate by the vagus nerve, known as high-frequency heart rate 
variability (HRV) (Thayer and Lane 2000; Appelhans and Luecken 2006; Thayer and Lane 
2009; Thayer et al. 2012). HRV in the high frequency range (0.15 – 0.40 Hz) is mediated by 
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parasympathetic influences on the sinoatrial node of the heart (Berntson et al. 1997). Among 
healthy individuals, heightened phasic HRV in response to emotional challenge has been 
shown to reflect regulatory efficacy (Butler et al. 2006; Segerstrom and Nes 2007), whereas 
individuals with difficulties in emotion regulation exhibit lower HRV at rest (Williams et al. 
2015) and blunted phasic HRV during emotion regulation tasks (Di Simplicio et al. 2011). 
Similarly, substance dependent patients with deficits in regulation of attention, emotion, and 
appetitive urges have been shown to exhibit attenuated HRV at rest (Ingjaldsson et al. 2003; 
Quintana et al. 2013) and when attempting to regulate reward responses (i.e., craving) to 
addiction-related cues (Garland et al. 2012a). At the same time, elevated HRV is also elicited 
in response to a wide range of appetitive stimuli (Rajan et al. 1998; Inagaki et al. 2005; 
Culbertson et al. 2010; Stockhorst et al. 2011; Erblich et al. 2011; Garland et al. 2012b; Udo 
et al. 2013). Relatedly, upregulating positive emotions is associated with increased vagally-
mediated HRV over time (Kok et al. 2013). Taken together, these findings indicate that HRV 
may be a useful means of assessing emotion regulation capacity and responsivity to 
rewarding stimuli among prescription opioid misusing chronic pain patients.
To date, few studies have examined emotion regulation among individuals in pain, and those 
that have were largely focused on the effects of emotion regulation on acute pain experience. 
Among healthy individuals, downregulating negative emotions through reappraisal (Lapate 
et al. 2011; Hampton et al. 2015) and acceptance (Braams et al. 2012; Kohl et al. 2013), and 
upregulating positive emotions through positive mood induction (Finan and Garland 2015) 
have been associated with the ability to decrease experimentally-induced pain and pain-
related cardiovascular responses. In contrast to these adaptive strategies, maladaptive forms 
of emotion regulation (e.g., suppressing negative emotions) have been shown to increase 
acute pain induced in the laboratory (Quartana et al. 2010). Among chronic pain patients, 
maladaptive emotion regulation strategies like emotion suppression have been shown to 
exacerbate pain under stressful conditions (Burns 2006) by increasing physiological 
reactivity to pain and stress (Burns et al. 2011). Neuroimaging research has suggested that 
the regulation of pain and emotion share overlapping neural substrates, including cortico-
limbic-striatal circuits (Salomons et al. 2014) which partially overlap with the central 
autonomic network thought to govern HRV. These studies suggest a linkage between 
emotion regulatory capacity and pain, yet it is unclear whether chronic pain patients who use 
and misuse opioids evidence emotion regulation deficits. In that regard, though previous 
research has demonstrated associations between opioid misuse and negative affectivity in 
chronic pain samples (Martel et al. 2014; Wasan et al. 2015; Edwards et al. 2016), to our 
knowledge, no prior study has investigated emotion regulatory deficits among opioid-using 
and misusing chronic pain patients with a performance-based, biobehavioral measure of 
proactive emotion regulation.
The present study aimed to 1) establish whether prescription opioid misusers with chronic 
pain evidence attenuated emotion regulatory capacity (as indicated by HRV responses) on an 
emotion regulation task relative to chronic pain patients who take opioids as medically 
prescribed and 2) to determine whether opioid dose is significantly correlated with blunted 
positive emotion regulation capacity.
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2. Method
Participants (N=40; see Table 1 for demographic/clinical characteristics) were recruited from 
primary care and specialty pain clinics, and met inclusion criteria if they reported having a 
chronic pain condition and had taken opioid analgesics daily or nearly every day for at least 
the past 90 days (Chou et al. 2009). Participants were instructed to take their prescribed 
opioid medication as usual on the day of the study. Following informed consent, participants 
completed self-report measures of opioid dose, pain severity and location, opioid misuse 
behaviors, and opioid craving. Then ECG electrodes were attached, and participants sat 
quietly for a 5-minute resting baseline period. After this resting baseline, participants then 
completed a blocked emotion regulation task while ECG was recorded. In between the four 
blocks of the emotion regulation task, participants made affect ratings to report their 
emotional response to each of the emotion regulation conditions. The study protocol was 
approved by the University of Utah IRB. All procedures complied with standards 
propounded in the Helsinki Declaration of 1975.
Prescription opioid misuse was determined by scores on the self-reported Current Opioid 
Misuse Measure (COMM; α=.83) (Butler et al. 2007). The original COMM validation study 
found that a score of ≥9 was suggestive of prescription opioid misuse among chronic pain 
patients. Based on a validated cut-point of 9 on the Current Opioid Misuse Measure 
(COMM) (Butler et al. 2007), participants were placed into one of two groups: a group of 
chronic pain patients who engaged in opioid misuse behaviors (misusers, n=28), and a group 
of chronic pain patients who took prescription opioids without engaging in opioid misuse 
(non-misusers, n=12).
2.1 Measures
Emotion regulation task—The study utilized an emotion regulation paradigm (Jackson 
et al. 2000; Ochsner et al. 2002) that was comprised of 120 trials, each presented for 6 
seconds, separated by a 500 ms fixation cross. There were four conditions, each presented in 
one of four randomized, counterbalanced blocks: “view negative,” “reappraise negative,” 
“view positive,” and “savor positive.” The “reappraise negative” condition instructed 
participants to reinterpret the image content to decrease emotional reactions to the image. 
The “savor positive” condition, which corresponded to typical “increase positive” 
instructions on emotion regulation tasks (e.g., Kim and Hamann 2007), instructed 
participants to imagine experiencing the positive event occurring in the image, and to focus 
on enjoyable aspects of the image and their own positive emotional response to the image. 
The “view” conditions instructed participants to simply view the image without trying to 
change their emotional experience. After each block, participants rated their current 
emotional state from 1 (most negative) to 9 (most positive). Stimuli included positive images 
of natural rewards (e.g., social affiliation, athletic victories) and negative images (e.g., 
violence, injury) from the International Affective Picture System (Lang et al. 1997) (see 
Supplementary Materials for more detail).
Opioid use and misuse—Morphine equivalent daily opioid dose (MEDD) was obtained 
by self-report and corroborated by medical chart review. The COMM (α=.82) (Butler et al., 
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2007) was used to assess prescription opioid misuse. Participants responded to 17 items 
rated on a Likert scale (0 = never, 4 = very often) regarding how often in the past 30 days 
they had engaged in behaviors linked with opioid misuse or took opioid medication in 
excessive doses or ways other than how it was prescribed.
Opioid craving—Opioid craving over the past week was assessed with two items rated on 
100mm visual analog scales (VAS): “In the past week, how much have you craved your pain 
medication?” and “In the past week, how often have you found yourself thinking about the 
next opioid dose.” Desire for opioids at the time of the emotion regulation protocol was 
assessed with a single VAS item: “How much do you want to take your opioids right now?” 
Similar VAS items have been used to assess opioid craving among chronic pain patients 
(Wasan et al. 2009).
Pain severity—Pain severity was measured with the four-item pain severity subscale from 
the Brief Pain Inventory (BPI; α=.88) a well-validated measure widely used to assess acute 
and chronic pain (Cleeland, 1994). Response options ranged from 0 (no pain) to 10 (pain as 
bad as I can imagine).
Emotional distress—Distress was measured with the 21-item Depression Anxiety Stress 
Scale (DASS), which provides a composite score of negative emotional symptoms (α=.93) 
(Antony et al. 1998).
HRV Measurement—Ag-AgCl electrodes were attached to participants’ right and left 
pectoral muscles. Electrocardiogram (ECG) data were sampled at 1000 Hz and recorded 
continuously throughout the protocol on a Biopac MP36 or MP150 (Biopac, Goleta, CA). 
Respiration rate was measured concurrently via the Biopac system to confirm that breathing 
fell within the respiratory frequency band (0.15 – 0.40 Hz).
2.2 Data Reduction and Analysis
With respect to the HRV analyses, R-R intervals were detected in the ECG data using 
automated routines in Acqknowledge 4.1 software (BIOPAC, Inc.). The R-wave file was 
then visually inspected to correct misidentified or omitted R-waves. Kubios 2.0 (Biosignal 
Analysis and Medical Imaging Group, University of Finland) was used to calculate beats-
per-minute (BPM) and for spectral analysis of R-waves. R-R interval data were segmented 
into five, 3.25 minute segments, each of which spanned the entire length of one of the five 
study conditions: resting baseline, “view negative,” “reappraise negative,” “view positive,” 
and “savor positive” blocks. HRV analyses were conducted on the entire segment length for 
each of these five conditions: a fast Fourier transform was applied separately to R-R interval 
data to extract normalized high-frequency HRV from a de-trended, end-tapered interbeat 
interval time series. The spectrum for the selected R-R interval segment was calculated via 
Welch’s periodgram method, in which R-R interval data were reduced using Kubios 2.0 
default settings of a window width of 128 seconds (with a window overlap of 50%). High-
frequency HRV in the respiratory frequency band (0.15 – 0.40 Hz) was selected as our 
estimate of vagally-mediated HRV. Analysis of respiration data showed that breathing fell 
within the respiratory frequency band (mean respiration rate .21 Hz at baseline, .22 Hz 
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during “view negative,” .23 Hz during “reappraise negative,” .21 Hz during “view positive,” 
and .22 Hz during “savor positive” blocks). Following Berntson (1997) and Malliani et al. 
(1994), we calculated HRV in normalized units to elucidate shifts in this frequency 
component that might otherwise be obscured by use of absolute units which are dependent 
on total HRV power. Normalization of HRV values produces statistical averages with 
distributions that converge more readily to normal distributions than do raw spectral band 
powers, and normalization tends to produce values that are more translatable across different 
research studies using similar tasks with different block lengths (Burr 2007). HRV was 
averaged for the baseline and each of the four emotion regulation task blocks.
To test our study hypotheses, we first conducted 2 (Group: Misuser, Non-misuser) × 5 
(Condition: baseline, view negative, reappraise negative, view positive, savor positive) 
ANOVAs on HRV and affect ratings during the emotion regulation task. Next, to isolate the 
effects of opioid misuse from the effects of other potential confounders on indices of 
emotion regulation, we controlled for MEDD, pain severity, emotional distress, and gender 
as covariates in a separate sensitivity analysis. To identify differential effects of opioid 
misuse status on various conditions of the emotion regulation task relative to the resting 
baseline, planned contrasts were used. Next, we examined opioid dose as a predictor of 
positive emotion regulatory inefficacy by correlating MEDD with reappraise-view and 
savor-view change scores in affect ratings (Felder et al. 2012). Then, we investigated the 
association between opioid craving (craving and thoughts about opioids in the past week, 
and current desire for opioids) and affect ratings during the emotion regulation task. The 
Bonferroni-Holm procedure was used to correct for multiple comparisons across these 12 
correlation coefficients. Lastly, we conducted a path model with bootstrapping of the 
indirect effect (Preacher and Hayes 2008) to examine affect rating variables that survived 
correction for multiple comparisons as mediators of the association between opioid misuse 
and craving.
3. Results
3.1 HRV and Affective Responses During Emotion Regulation
With regard to HRV responses, neither the main effect of Condition, F(4,35)=1.05, p=.37, 
η2partial =.03, nor the main effect of Group, were significant, F(1,35)=2.55, p=.12, η2partial=.
06. The omnibus Group × Condition interaction was significant, F(4,35)=2.92, p=.035, 
η2partial=.07, suggesting that the pattern of HRV responses across emotion regulation 
conditions significantly differed between opioid misusers and non-misusers. To ensure the 
robustness of this between-groups difference, we then controlled for potential confounders 
in a sensitivity analysis, and found that neither the main effect of Condition nor the main 
effect of Group were significant; however, the omnibus Group X Condition interaction was 
significant, F(4,35)=4.32, p=.005, η2partial=.11. Planned contrasts revealed that HRV 
increased to a significantly greater extent for non-misusers than for misusers from resting 
baseline to the “view positive” block, F(1,35)=8.46, p=.006, η2partial=.20, “savor positive” 
block, F(1,35)=4.78, p=.036, η2partial=.12, and “reappraise negative” block, F(1,35)=4.28, 
p=.046, η2partial=.11 (see Figure 1). Also, misusers did not show the differences in HRV 
from “view negative” to “reappraise negative” exhibited by nonmisusers, F(1,35)=5.21, p=.
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03, η2partial=.13. With regard to affective responses, the main effect of Condition was 
nonsignificant, F(4,32)=2.19, p=.07, η2partial=.06. Though the Group × Condition interaction 
was not significant, there was a significant main effect of Group, F(1,32)=4.55, p=.04, 
η2partial= .13, such that misusers reported significantly less positive affect (M affect 
rating=4.91, SE=.15) throughout the entire protocol than non-misusers (M affect 
rating=5.48, SE=.23).
3.2 Association Between Opioid Dose and Emotion Regulation Efficacy
Higher MEDD was significantly associated with lower positive emotion regulation efficacy, 
r=−.42, p=.006, but was not significantly correlated with negative emotion regulation 
efficacy, r=−.14, p=.41.
3.3 Association Between Pain and Emotion Regulation Efficacy
Pain severity was not significantly associated with either positive (r=−.16, p=.34) or negative 
emotion regulation (r=−.09, p=.61) efficacy,
3.4 Association Between Affect Ratings and Craving
Craving in the past week was associated with lower affect ratings during the “view positive” 
condition (r=−.39, p=.01). Frequent thinking about the next opioid dose was associated with 
lower affect ratings during the “view positive” (r=−.34, p=.03) and “savor positive” (r=−.34, 
p=.04) conditions. Current desire for opioids at the time of the emotion regulation task was 
associated with lower affect ratings during the “view positive” (r=−.49, p=.001), “savor 
positive” (r=−.31, p=.05), and “reappraise negative” (r=−.31, p=.05) conditions. None of the 
other correlations were significant, and none of the significant correlations survived 
correction for multiple comparisons save for the association between current desire for 
opioids and lower affect during the “view positive” condition.
3.5 Path Model
The sole affect rating variable that survived multiple corrections (affect during “view 
positive”) was entered into a path model as a mediator of the association between opioid 
misuse and current desire for opioids (Figure 2). Because opioid dose was correlated with 
positive emotional responses during the emotion regulation task, MEDD was used as the 
single covariate in this model. The bootstrapped unstandardized indirect effect was .74, and 
the 95% confidence interval ranged from .08 to 1.61. Thus, the indirect effect of attenuated 
positive affect during processing of positive emotional stimuli on desire for opioids was 
statistically significant.
4. Discussion
In this study of chronic pain patients receiving extended opioid pharmacotherapy, patients 
who surpassed the validated opioid misuse cut-point on the COMM, a measure designed to 
assess opioid misuse, exhibited significantly blunted HRV responses to positive emotional 
stimuli, and less positive affect, in general, compared to opioid non-misusers. Also, patients 
who exceeded the opioid misuse cut-point evidenced emotion regulatory deficits, as 
indicated by attenuated capacity to increase autonomic regulation during reappraisal of 
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negative stimuli. Moreover, opioid dose was significantly inversely associated with positive 
emotion regulation, such that patients taking comparatively higher opioid doses were less 
able to proactively increase positive affect via savoring positive images than patients taking 
low dose opioids. Finally, reduced positive affect in response to viewing positive images was 
associated with heightened opioid craving.
Study findings provide preliminary support for allostatic models of prescription opioid 
misuse (Shurman et al. 2010; Garland et al. 2013; Elman and Borsook 2016), which assert 
that chronic exposure to opioids in the context of chronic pain produces a downward shift in 
the hedonic set point, resulting in insensitivity to natural rewards and a dysphoric mood 
state. According to such models, opioid-induced dysregulation of hedonic homeostasis is 
then thought to drive opioid misuse behaviors, which eventually become habitual, 
undermining self-control and miring the individual in a downward spiral of craving and 
compulsive opioid use. In that regard, opioid misusers in the current study exhibited 
dampened HRV responses during negative emotion regulation relative to non-misusers, who 
evidenced increases in HRV when reappraising negative emotional images. Indeed, non-
misusers in the present study showed a HRV response profile during emotion regulation that 
was similar to that of healthy controls, who exhibit increases in HRV during reappraisal 
relative to passive exposure to negative stimuli (Di Simplicio et al. 2012). The observed 
attenuation of HRV responses during reappraisal among the opioid misusers in our sample 
implicates the presence of poor central-autonomic integration with consequent deficits in 
top-down cognitive control over bottom-up affective responding (Thayer and Lane 2009), 
reflected by diminished flexibility in parasympathetic cardiovascular tone during cognitive 
regulation of negative emotions.
At the same time, opioid misuse in the current sample was selectively associated with 
blunted HRV responses when passively processing positive but not negative emotional 
stimuli. In light of prior studies demonstrating that HRV increases in response to 
presentation of rewarding stimuli (Inagaki et al. 2005; e.g., Garland et al. 2012b), this 
finding suggests that opioid misuse may be associated with reduced reward responsiveness. 
Further, in the present sample, high-dose opioid use and misuse were correlated with 
impairments in upregulating positive affective responses, and path analysis indicated that the 
association between opioid misuse and desire for opioids was statistically mediated by 
reduced affective responses to positive stimuli. This latter finding provides support for 
allostatic models (Shurman et al. 2010; Garland et al. 2013; Elman and Borsook 2016) that 
suggest opioid misuse may lead to insensitivity to natural rewards, which in turn may impel 
craving for opioids as means of obtaining hedonic equilibrium. Overall, autonomic and 
affective results from the present study add to the emerging body of literature demonstrating 
hedonic dysregulation, reward processing deficits, and reward-related pathophysiology 
among chronic pain patients on high dose opioids and those at risk for prescription opioid 
misuse (Younger et al. 2011; Bunce et al. 2015; Garland et al. 2015a; Borsook et al. 2016).
However, given the cross-sectional nature of the current study, it is unknown whether the 
observed emotion regulatory impairments were a cause, correlate, or consequence of opioid 
misuse and dose escalation. In that regard, individuals with a dispositional inability to 
regulate distressing emotions may turn to substance misuse as a means of self-medicating 
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emotional distress (Khantzian 1997). From this perspective, emotional distress from 
comorbid chronic pain and affective dysregulation might impel self-medication motives and 
thereby increase vulnerability to prescription opioid misuse. Indeed, epidemiological studies 
indicate that mood and anxiety disorders are often antecedent to the onset of opioid misuse 
and dependence (Green et al. 2011; Martins et al. 2012), and in a sample of prescription 
opioid dependent individuals in acute detoxification and long-term outpatient treatment, 
94% reported frequent misuse of opioids to self-medicate negative affect (Garland et al. 
2014c). Given the common occurrence of prescription opioid misuse as a means of self-
medicating negative emotions, it is possible that some participants in the study who were 
classified as opioid misusers may have suffered from preexisting emotion dysregulation 
(perhaps due to untreated pain) prior to the onset of opioid use. To account for this 
possibility, we included trait-level emotional distress and pain severity as covariates in our 
analyses, and after controlling for these variables, we found that opioid misusers continued 
to evidence blunted emotion regulatory capacity when compared to non-misusers. Despite 
these statistical controls, this alternative interpretation cannot be ruled out due to the cross-
sectional nature of the study. Most likely, recursive feedback loops are at play, such that 
individuals with dispositional emotion regulation deficits may be more likely to engage in 
opioid misuse and opioid dose escalation, which, when prolonged over time, might amplify 
their propensity towards emotion dysregulation. Longitudinal investigations are needed to 
yield fine-grained, temporally dynamic causal models of the relations examined in this 
study.
Moreover, the study was limited by the fact that we characterized patients as opioid misusers 
based on their score on a self-report instrument (the COMM). Because some patients may be 
reluctant to admit to opioid misuse on a self-report measure, reporting bias is possible. For 
this reason, we may not have been able to correctly classify all the misusers in the sample. 
Nonetheless, participants were assured of confidentiality, and the majority endorsed opioid 
misuse on the COMM. Future studies should triangulate self-reports of opioid misuse with 
clinical interviews and review of data from legally-mandated prescription monitoring 
programs. In addition, interpretation of study findings is limited by the fact that we did not 
collect data on use of medications other than opioids which might modulate HRV (e.g., 
sedatives, antidepressants, beta blockers, etc.). It is possible that misusers and non-misusers 
may have differed with regard to other medication usage. That said, the lack of significant 
between-groups differences in resting baseline HRV and HRV responses to viewing negative 
emotional stimuli suggests that the observed HRV differences in the reappraise negative, 
look positive, and savor positive conditions were not driven by mere pharmacologic effects 
of other medications that might dampen HRV. If the misuse and non-misuse groups did in 
fact differ on use of other medications that dampen HRV, it is likely that HRV differences 
would have been observed in resting HRV and HRV response during the negative look 
conditions. Nonetheless, future studies should carefully quantify medication usage to 
prevent possible confounding by other medications. Lastly, we instructed participants to take 
their opioids as prescribed on the day of the emotion regulation testing session to prevent 
opioid withdrawal which might have had deleterious effects on participants’ health and 
cognitive performance. The acute pharmacologic effects of opioids might have influenced 
performance on the emotion regulation task. To account for this possibility, we included 
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morphine equivalent daily dose as a covariate in sensitivity analyses. Longitudinal 
investigations are needed to determine the effects of high dose opioids on emotion 
regulation, and whether such effects are undergirded by changes in brain systems implicated 
in salience attribution (e.g., dopaminergic) and hedonic responses (e.g., endogenous opioid) 
that are dysregulated in the context of chronic pain and addiction (Elman and Borsook 
2016).
In sum, findings from the present exploratory study, though preliminary, add to the growing 
body of literature suggesting that the comorbidity of chronic pain and opioid misuse is 
linked with emotion regulation and reward processing deficits. Should these findings be 
replicated in larger and better controlled studies, they may have important implications for 
treatment development. Indeed, interventions that restructure reward processes by enhancing 
positive emotion regulation (e.g., Mindfulness-Oriented Recovery Enhancement, see 
Garland 2016) may effectively remediate affective deficits among opioid-misusing patients, 
and possibly attenuate addictive tendencies towards opioids. In that regard, enhancing 
natural reward responsiveness via cognitive training appears to be associated with decreased 
opioid craving and opioid misuse among chronic pain patients (Garland et al. 2014a; 
Garland et al. 2014b). More research is needed to determine the mechanistic role of emotion 
regulation in modulating hedonic functions underpinning the comorbidity of chronic pain 
and opioid misuse.
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Figure 1. 
High-frequency heart rate variability (HF-HRV, in normalized units) responses at baseline 
and during conditions of the emotion regulation task, by opioid misuser and nonmisuser 
groups, controlling for covariates including gender, morphine equivalent daily opioid dose, 
pain severity, and emotional distress. Means and error bar (standard error) are plotted as 
function of blocks across the two groups.
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Figure 2. 
Path model testing positive affect during visual processing of positive emotional stimuli 
(“view positive” condition on the emotion regulation task) as a mediator of the association 
between opioid misuse and current desire for opioids, controlling for morphine equivalent 
daily opioid dose. Statistical parameters in brackets represent the association between opioid 
misuse and current desire for opioids in the absence of the mediating variable. Solid arrows 
denote statistical significant pathways whereas dotted arrows denote non-significant 
pathways.
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Table 1
Demographic and Clinical Characteristics of the Opioid-Treated Chronic Pain Sample (N = 40).
Measure Non-Misusers
(n = 12)
Misusers
(n = 28)
Difference Tests
Female, N (%) 2 (17%) 10 (36%) X2=1.45, p=.23
Age 42.67 ± 16.83 39.79 ± 13.31 t=.58, p=.57
Racial/ethnic background, N (%) X2=.52, p=.92
  African American 1 (8%) 3 (11%)
  Caucasian 10 (83%) 22 (79%)
  Latino 1 (8%) 2 (7%)
  Asian/Pacific Islander - 1 (4%)
Primary Pain condition, N (%) X2=1.84, p=.61
  Low back pain 5 (42%) 17 (61%)
  Joint Pain 4 (33%) 6 (21%)
  Cervical Pain 1 (8%) 3 (11%)
  Other 2 (17%) 2 (7%)
Pain severity (BPI) 6.35 ± 1.81 5.89 ± 1.48 t=.85, p=.40
Emotional distress (DASS) 8.25 ± 4.86 19.43 ± 11.91 t=4.21, p<.001
Opioid misuse (COMM) 5.00 ± 2.34 16.39 ± 6.44 t=8.19, p<.001
Opioid craving in past week (VAS) 7.00 ± 10.33 24.00 ± 26.23 t=2.90, p=.006
Thoughts of opioids in past week (VAS) 5.36 ± 8.05 24.82 ± 28.31 t=3.31, p=.002
Current desire for opioids (VAS) 26.82 ± 32.37 47.9 ± 48.53 t=1.94, p=.06
Morphine equivalent daily dose 55.94 ± 48.53 157.11 ± 226.21 t=2.25, p=.03
Primary opioid type, N (%)† X2=.82, p=.84
  Hydrocodone 3 (25%) 9 (32%)
  Oxycodone 3 (25%) 7 (25%)
  Tramadol 5 (42%) 8 (29%)
  Other 1 (8%) 4 (14%)
Note: BPI = Brief Pain Inventory (Cleeland 1994); COMM = Current Opioid Misuse Measure (Butler et al. 2007); DASS =Depression Anxiety 
Stress Scale-21 (Antony et al. 1998); VAS = visual analogue scale (Wasan et al., 2009).
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